From these results, it is possible that AAT prior to enzalutamide administration delayed the time to enzalutamide administration and may have shortened the OS after enzalutamide administration during the entire period of prostate cancer treatment. This evidence concerns the gene SERPINA1 and Familial prostate cancer.